RE:From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 months
JPM 2024: Biotech Companies Mapping Out Their Future, and a New Round of M&A Spree Begins
Momentum in the Field of Rare Diseases
https://www.geneonline.com/jpm-2024-biotech-companies-mapping-out-their-future-and-a-new-round-of-ma-spree-begins/
In the United States and European Union, pancreatic cancer classifies as a rare disease, allowing drug developers to apply for orphan medicinal product (OMP) designation.
ONCY's pelareorep is preparing for a registration study in the desginated rare disease space of advanced/metastatic pancreatic cancer.